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ABSTRACT
Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)-CRISPR-associated (Cas)
systems of type I use a Cas ribonucleoprotein
complex for antiviral defense (Cascade) to mediate
the targeting and degradation of foreign DNA. To
address molecular features of the archaeal type
I-A Cascade interference mechanism, we estab-
lished the in vitro assembly of the Thermoproteus
tenax Cascade from six recombinant Cas proteins,
synthetic CRISPR RNAs (crRNAs) and target DNA
fragments. RNA-Seq analyses revealed the process-
ing pattern of crRNAs from seven T. tenax CRISPR
arrays. Synthetic crRNA transcripts were matured
by hammerhead ribozyme cleavage. The assembly
of type I-A Cascade indicates that Cas30 and Cas300
are an integral part of the complex, and the interfer-
ence activity was shown to be dependent on the
crRNA and the matching target DNA. The
reconstituted Cascade was used to identify
sequence motifs that are required for efficient DNA
degradation and to investigate the role of the
subunits Cas7 and Cas300 in the interplay with
other Cascade subunits.
INTRODUCTION
The coevolution of viruses with their prokaryotic hosts led
to the development of speciﬁc and highly divergent
antiviral prokaryotic immune systems. One complex
group of adaptive immune systems that is widespread in
bacterial and archaeal genomes is termed Clustered
Regularly Interspaced Short Palindromic Repeats
(CRISPR)-CRISPR-associated (Cas). Cells that harbor
these systems can be immunized against the attack of
viruses by the integration of a virus-derived genome
fragment into the host genome (1). The genetic memory
of previous infections is mediated by CRISPR loci, which
consist of a series of short repeat sequences (typically 24–
37 bp) that are separated by spacer sequences (2–4). Cas
proteins are often encoded in proximity to the CRISPR
loci and are key players during all phases of immunization
and protection of the cell (5,6). In the ﬁrst phase, the
adaptation, the injected viral DNA is recognized and a
fragment is inserted into the host CRISPR array (7–9).
This activity is often dependent on a short conserved
sequence (2–5 bp) deﬁned as the protospacer adjacent
motif (PAM) that ﬂanks the original spacer sequence
(termed protospacer) in the viral genome (10,11). The
genetic imprint is activated by the transcription of the
CRISPR into a long precursor-crRNA (pre-crRNA),
which is typically processed by the endoribonuclease
Cas6 into short crRNAs that are characterized by an 8-
nt 50-hydroxyl repeat tag, a complete spacer sequence and
a 20–30 cyclic phosphate repeat end (12–18). During a
repeated viral attack, the mature crRNAs can be
incorporated into a large Cas ribonucleoprotein interfer-
ence complex to target the viral DNA for degradation
(19–21).
These basic principles of CRISPR-Cas immunity are
conserved, but careful computational and biochemical
analyses of the differences among the executing interfer-
ence machines, the composition of conserved Cas marker
proteins and the nature of the targeted nucleic acids led to
the identiﬁcation of three distinct major types and several
subtypes of CRISPR-Cas systems (5,22). The type
I CRISPR-Cas systems can be further divided into six
different subtypes (subtypes I-A to I-F), and the respective
interference complex is termed Cascade (19). In type III
systems, interference is executed by the Csm (subtype III-A,
targeting DNA) or Cmr complex (subtype III-B, targeting
RNA) (23–25). In contrast, bacterial type II systems are
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characterized by the single large multifunctional protein
Cas9, which is involved in both the maturation of
crRNAs and the interference of DNA (26–28).
First details of the Cascade structure and the molecular
mechanism were obtained for type I-E systems of
Escherichia coli. The I-E Cascade shows a seahorse-shaped
architecture with a size of 405 kDa and is composed of the
conserved subunits Cas6e, Cas7, Cas5e and the subtype-
speciﬁc nucleic acid-binding proteins Cse1 and Cse2
(19,29,30). The helical backbone of I-E Cascade is
formed of six Cas7 copies that are tightly bound to a
mature crRNA (31,32). The I-E Cascade facilitates the
base pairing of the bound crRNA with the complementary
DNA by screening for the short PAM sequence, resulting
in strand invasion of the RNA and additional displace-
ment of the non-complementary strand to form the
R-loop structure, which recruits Cas3 to degrade the
targeted viral DNA (18,33–36). The effector protein
Cas3 contains a DExH-like helicase domain (Cas30) and
a HD phosphohydrolase domain (Cas300), which are
responsible for the unwinding of double-stranded DNA
(dsDNA) and cleavage of single-stranded DNA
(ssDNA) in dependence of adenosine triphosphate
(ATP) and divalent metal ions, respectively (37–39).
The type I CRISPR-Cas subtypes differ in Cas protein
content, which implies divergent Cascade assembly
strategies and functional differences. Comparative
studies of these different Cascade complexes will help to
gain insight into the evolution and propagation of
CRISPR-Cas systems, the integration of one or multiple
immunity systems into the cellular protein network and
the adaptation mechanisms to diverse prokaryotic envir-
onments (5,40). Analysis of the CRISPR-Cas system of
the crenarchaeon Thermoproteus tenax identiﬁed a type
I-A Cascade module (csa5, cas7, cas5a, cas30, cas300,
cas8a2), essential genes for the adaptation of foreign
DNA (cas1/cas2, cas4), a type III-A gene cluster, a
second subset of a Cascade module and seven CRISPR
loci spread throughout the genome (41,42). In Sulfolobus
solfataricus, the type I-A Cascade sub-complex of Cas7
and Cas5a was identiﬁed and shown to bind crRNA
and complementary ssDNA. The recombinant Cas7
proteins assembled into multimeric right-handed helical
structures (43).
Here, we show the assembly of a complete type I-A
Cascade from individual in vitro-produced Cas proteins,
ribozyme-processed synthetic crRNAs and short
protospacer DNA fragments. The strategy for the
protein body assembly of the mature Cascade follows
the co-refolding of insoluble recombinant I-A Cas
proteins from bacterial inclusion bodies to recover the
six protein complex. Synthetic crRNAs were created
by in vitro transcription of crRNA constructs fused to
cis-acting hammerhead ribozymes. The assembly of the
Cascade ribonucleoprotein complex yielded active mol-
ecules that showed crRNA-speciﬁc DNA targeting and
degradation. This in vitro assembly strategy allowed us
to obtain insights into the Cascade assembly and DNA
cleavage mechanism and to identify the PAM require-
ments for target degradation.
MATERIALS AND METHODS
Strains and growth conditions
Cells of T. tenax Kra1 (DSM 2078) grown
heterotrophically in Thermoproteus medium (44) were a
gift from R. Hensel (Essen). E. coli strains TOP10
(Invitrogen) and Rosetta2(DE3)pLysS (Stratagene) were
cultured in LB medium at 37C shaking at 200 rpm. For
protein production, 1mM isopropyl-b-D-1-thiogalacto-
pyranoside (IPTG) was added to a growing culture
(OD600: 0.6) and incubated for 4 h.
Isolation of small RNAs, production of crRNAs and DNA
substrates
For the preparation of T. tenax small RNAs (<200 nt),
0.1 g pelleted cells were lysed by homogenization and sub-
sequently isolated according to the mirVanaTM miRNA
Isolation Kit (Ambion). To generate synthetic crRNAs,
forward and reverse complementary DNA oligonucleo-
tides (cr5.2h or cr5.13h, respectively) were synthesized
that contained a selected spacer sequence (spacer 5.2 or
spacer 5.13) and were fused with the sequence of a
minimal cis-acting hammerhead ribozyme at the 50-end
(Supplementary Table SI). The oligonucleotides were
phosphorylated, hybridized and cloned under control
of the T7 RNA polymerase promoter sequence
(cr5.2h: BamHI/HindIII, cr5.13h: HindIII/EcoRI) into
pUC19. The crRNA was prepared by run-off transcrip-
tion in a reaction containing 40mM HEPES/KOH, pH
8.0, 22mM MgCl2, 5mM dithiothreitol, 1mM spermi-
dine, 4mM of ATP, CTP, GTP and UTP, 20U RNase
inhibitor, 1 mg T7 RNA polymerase and template DNA
[PCR products with sequence-speciﬁc primers (cr5.2PCRf/
r or cr5.13PCRf/r, respectively)] at 37C for 4 h. For the
self-cleaving reaction of the hammerhead ribozyme, the
transcription reaction was directly diluted with 4
volumes of 30mM MgCl2 in DEPC-H2O and incubated
for 1 h at 60C. The cleaved crRNA was puriﬁed by
phenol/chloroform extraction (pH 5.2), EtOH
precipitated with the addition of glycogen (1:100, v/v),
mixed with 2 formamide loading buffer (95%
formamide, 5mM EDTA, pH 8.0, 2.5mg bromophenol
blue, 2.5mg xylene cyanol), heated for 5min at 95C,
separated by a denaturing-PAGE (8M urea, 1 TBE,
10% polyacrylamide) next to an RNA marker (low
range ssRNA ladder, NEB) and visualized by toluidine
blue staining. The gel bands were cut out and eluted over-
night on ice in 500ml elution buffer (20mM Tris–HCl, pH
7.5, 250mM sodium acetate, 1mM EDTA, pH 8.0, 0.25%
SDS) and EtOH precipitated. All DNA oligonucleotides
used for cloning and as cleavage substrates were cus-
tom-synthesized (Euroﬁns MWG Operon,
Supplementary Table SI).
RNA sequencing
The isolated small RNA was treated with T4
Polynucleotide Kinase (PNK) to ensure proper termini
for adapter ligation (45). First, for the dephosphorylation
of 20–30-cyclic phosphate termini, 10 mg of RNA was
incubated at 37C for 6 h with 20U T4 PNK (NEB) in
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1 T4 PNK buffer. Subsequently, 1mM ATP was added,
and the reaction mixture was incubated for 1 h at 37C to
generate monophosphorylated 50-termini (46). RNA
libraries were prepared with an Illumina TruSeq RNA
Sample Prep Kit (Ambion), and sequencing on an
Illumina HiSeq2000 sequencer was performed at the
Max-Planck Genome Centre, Cologne, Germany. Reads
were mapped to the T. tenax reference genome
(FN869859) with CLC Genomics Workbench 6.0.
Puriﬁcation of Cascade proteins
The gene constructs of csa5, cas7, cas5a, cas30, cas300 and
cas8a2 in pET24a(+) (Novagen) were used as previously
described (41). Cas300 mutants were created using the
QuikChange site-directed mutagenesis protocol
(Stratagene) according to the manufacturer’s instructions.
Established mutations were conﬁrmed by sequencing
(MWG Euroﬁns). Soluble Csa5 could be puriﬁed, as
cells were homogenized in buffer 1 (100mM HEPES/
KOH, pH 7, 10% glycerol, 10mM ß-mercaptoethanol
(ß-Me), 10mM CaCl2, 300mM NaCl), lysed, cleared by
centrifugation (45 000 g, 1 h, 4C) and heat precipitated
(30min, 90C). The cleared supernatant (14 000 g,
30min, 4C) was dialyzed overnight in salt-free lysis
buffer 1 and puriﬁed via a Hi Screen Blue FF afﬁnity
column using a FPLC A¨kta-Puriﬁcation system
(GE Healthcare) eluted with a linear salt gradient (0–
2M NaCl) at 420mM NaCl. Fractions containing Csa5
were pooled, dialyzed overnight in salt-free buffer 1 and
puriﬁed via an anion-exchange chromatography with a
MonoQ 5/50 GL column (GE Healthcare) eluted with a
linear salt gradient (0–1M NaCl) at 100mM NaCl. For
pull-down assays of Cascade in vivo, Csa5 with a
C-terminal 6 His-tag was used as a bait protein.
Therefore, csa5 was cloned into pET20b(+), protein
expressed and cells lysed in buffer 1 without CaCl2. The
Csa5-His protein was puriﬁed from E. coli cell lysate by
Ni-NTA afﬁnity chromatography (HisTrap HP, GE
Healthcare) and eluted with a linear imidazole gradient
(0–500mM) at 150mM imidazole. Cas7 was puriﬁed by
cell lysis in buffer 1, heat precipitation at 80C and cation
exchange chromatography with Heparin Sepharose
(GE Healthcare) as described earlier (41). Additionally,
the Cas7 full-length protein was expressed as a recombin-
ant His-SUMO-tagged fusion protein using
BL21-Gold(DE3)Star pRARE (Stratagene) overnight at
18C. The cells were lysed by sonication in buffer
2 (100mM potassium phosphate, pH 7.5, 500mM NaCl,
10% glycerol, 1mM ß-Me) supplemented with 20mM
imidazole, benzonase (NEB) and protease inhibitors
(Roche), and Cas7-SUMO was further puriﬁed using
Ni-NTA afﬁnity chromatography. The salt concentration
was lowered to 100mM NaCl in 50mM Tris, pH 7.5, and
the His-SUMO-tag was cleaved off by adding SUMO
protease overnight during dialysis. The protein was
further puriﬁed over a HiTrap Heparin Sepharose HP
column (GE Healthcare) to remove non-speciﬁcally
bound nucleic acids. Size-exclusion chromatography on
a Superdex 75 column (GE Healthcare) was preformed
as a ﬁnal step of puriﬁcation in buffer 3 (100mM NaCl,
50mM Tris, pH 7.5, 10% glycerol, 5mM dithiothreitol).
The insoluble proteins Cas5a, Cas30, Cas300 and Cas8a2
were puriﬁed from inclusion bodies and solubilized in
4M guanidine hydrochloride (GdmCl). The purity of
all proteins was determined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE)
and Coomassie blue staining alongside the protein
marker (ColorPlusTM prestained protein ladder,
broad range, NEB). The protein concentration was
determined by the Bradford protein quantiﬁcation
method (BioRad).
Reconstitution assays
The reconstitution of the Cascade complex was previously
described (41). Brieﬂy, equal amounts (300mg) of each
solubilized protein Cas5a, Cas30, Cas300 and Cas8a2 were
mixed with the puriﬁed proteins Csa5 and Cas7 in recon-
stitution buffer (3.5M GdmCl, 100mM HEPES/KOH,
pH 7, 5% glycerol, 10mM ß-Me, 10mM MgCl2,
300mM NaCl) and the denaturing agent was removed
via stepwise dialysis into GdmCl-free buffer at room tem-
perature. Aggregated proteins were precipitated
(14 000 g, 30min, 4C), soluble proteins concentrated
with centrifugal ﬁlter units (MWCO: 10 kDa) and
analyzed by SDS–PAGE. The reconstitution of all 63
subunit combinations was tested via rapid dilution into
1ml GdmCl-free reconstitution buffer of equal amounts
(25mg) of each subunit. To minimize aggregation, the
protein solution was added drop-wise (5 mg total protein)
to the reconstitution buffer. Aggregated proteins were
precipitated (14 000 g, 30min, 4C), soluble proteins
were trichloroacetic acid (TCA)-precipitated and the
identical amounts of supernatant and pellet analyzed by
SDS–PAGE.
Pull-down assays and mass spectrometry analyses of
in vivo Cascade proteins
To determine the protein–protein interaction in vivo,
pull-down assays were performed with C-terminal
His-tagged Csa5 used as a bait protein bound to a cobalt-
chelate matrix and T. tenax cell extract as a prey. For the
production of cell-free T. tenax extract, 1 g cells were resus-
pended in lysis buffer 3 (100mM HEPES/KOH, pH 7.5,
300mM ß-Me) and lysed as described elsewhere (47). To
stabilize the interaction of proteins, a chemical cross-
linking with formaldehyde was performed. One hundred
micrograms puriﬁed Csa5, 1mg cell extract and 1% for-
maldehyde (37% formaldehyde/10% MeOH) were mixed,
incubated for 15min on ice and the reaction stopped by the
addition of 200mM glycine for 5min on ice. Subsequently,
the pull-down assay was performed according to the
ProFound Pull-Down PolyHis Protein:Protein
Interaction Kit (Pierce). The cross-linked protein:cell
extract was incubated for 30min at 4C on the cobalt
resin, washed ﬁve times with 40mM imidazole in buffer 1
without CaCl2 and eluted at 290mM imidazole. Proteins
were TCA-precipitated, separated by SDS–PAGE and
visualized with silver staining (Pierce Silver Stain Kit).
For the mass spectrometry analysis, the protein:cell
extract was pelleted by EtOH precipitation and digested
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in solution in the presence of urea as described previously
(48). The resultant peptides were desalted using STAGE
tips (49). Further, the desalted peptides were analyzed by
liquid chromatography tandem mass spectrometry on an
LTQ Orbitrap Velos instrument (Thermo Fischer
Scientiﬁc) under standard conditions. The protein identiﬁ-
cation was performed with MaxQuant (version 1.2.2.5)
using the Andromeda search engine (50,51).
Protein–protein and protein–RNA interaction assays
The protein–protein interaction and the native molecular
mass of Cascade or the Cas7 subunit was determined by
size-exclusion chromatography with a Superdex 200 10/300
preparatory-grade column (GE Healthcare, 24ml). Protein
containing fractions were TCA-precipitated [1:4 of 100%
(v/v)] and analyzed by SDS–PAGE. To verify the binding
of Cascade to crRNA, 50mg of synthetic crRNA was added
to 500mg of reconstituted Cascade complex incubated at
65C for 30min to facilitate RNA binding and separated
by gel ﬁltration. Fractions were split and protein extracted
via TCA precipitation and analyzed during separation
on SDS–PAGE, whereas RNA was isolated by Proteinase
K treatment (10ml, 6U Proteinase K, 30min at 37C),
phenol/chloroform extraction, EtOH precipitation and de-
tection via denaturing-PAGE (10% polyacrylamide) and
toluidine blue staining.
Electrophorectic mobility shift assay
The Cascade complex or the Cas7 subunit were tested for
the ability of binding synthetic crRNA in electrophorectic
mobility shift assays (EMSAs). As the binding of Cascade
was metal-independent, the complex was reconstituted in
the presence of 10mM CaCl2 instead of MgCl2 to reduce
RNA cleavage. A total of 5 pmol of the synthetic crRNA
substrate was 50-labeled with [g-32P]-ATP (5000 ci/mmol,
Hartmann Analytic) and T4 PNK (Ambion) for 2 h at
37C; the reaction stopped by the addition of formamide
loading buffer and the separation by denaturing-PAGE
(10% polyacrylamide). After autoradiographic exposure,
the RNA band were cut out, gel eluted and EtOH
precipitated. Up to 5 mM of reconstituted Cascade was
incubated with 2–4 nM of 50-labeled crRNA in binding
buffer (100mM HEPES/KOH, pH 7, 100mM NaCl,
10mM ß-Me, 50 ng yeast RNA) for 30min at 70C. The
reaction was immediately stopped on ice, mixed with 1
loading buffer (Qiagen) and Cascade:crRNA complexes
separated from free crRNA by non-denaturing
TBE-PAGE (6% polyacrylamide, 1 TBE). The ability
of monomeric Cas7 to bind to synthetic crRNA was
tested by incubating protein with 2–4 nM of 50-labeled
crRNA in binding buffer without yeast RNA for 30min
at 80C, ran on 2% TAE-agarose gels and visualized by
phosphorimaging. Binding of the two Cas7 versions
(Cas7, Cas7-SUMO) to contaminating nucleic acids
during the puriﬁcation process was veriﬁed by loading
100mg protein on 1% TAE-agarose gels stained with eth-
idium bromide alongside the DNA marker (2-log DNA
ladder, NEB). The speciﬁcation of the contaminated
nucleic acid was conducted by adding 2U DNase
I (RNase-free, NEB), 1 ng RNase A (biochemistry grade,
Ambion) or 25U benzonase (NEB) in the appropriate
reaction buffer to the protein solution and incubated for
30min at 37C before loading on agarose gels.
Transmission electron microscopy (TEM)
To further analyze samples of Cas7 puriﬁcations, 5 ml of
a concentrated protein solution was applied to car-
bon-coated 400 mesh copper grids. After blotting on a
ﬁlter paper, the samples were washed twice on a drop of
double distilled water and blotted each time. Finally, the
proteins were negatively stained with 2% (w/v) uranyl
acetate for 20 s, blotted again on ﬁlter paper and left for
air drying (52,53). Electron microscopy and further
analysis was carried out on a JEOL JEM-2100 transmis-
sion electron microscope (JEOL, Tokyo, Japan) operated
at 120 kV. The microscope was equipped with a 2k 2k
CCD camera F214 in combination with the EM-Menu
4 software (TVIPS, Gauting, Germany).
Nuclease assays
The reconstituted Cascade was tested for the nucleolytical
activity of the Cas300 subunit. A total of 5 pmol of the
ssDNA oligonucleotide (int 5.2_CCT for) was 50-labeled
with [g-32P]-ATP (5000 ci/mmol, Hartmann Analytic) and
puriﬁed as described earlier in the text. In all, 100 nM
refolded Cascade was incubated with 2 nM of 50-labelled
ssDNA in nuclease buffer (100mM HEPES/KOH, pH
7.0, 100mM NaCl, 5mM MgCl2, 5mM MnCl2, 10mM
ß-Me, 20 ng yeast total RNA) at 70C for 10min, the
reaction stopped via EtOH precipitation and resuspended
in 10mM Tris–HCl, pH 8.5, and formamide loading
buffer. Each sample was boiled, measured via scintillation
counting (Beckman LS6000) and samples with identical
counts per minute after normalization were loaded on
a 15% denaturing polyacrylamide gel alongside the low
molecular weight marker (10–100 nt, Affymetrix) running
in 1 TBE (8 watts, 2 hours). Cleavage products were
visualized by phosphorimaging.
To test for the cleavage of dsDNA, short substrates
were designed that mimic an invasive viral DNA.
Therefore, the spacer sequence of crRNA 5.2 or 5.13
was used, the different PAM added upstream and
ﬂanked with random sequences up- and downstream
(T7 promoter and T7 terminator, respectively) and each
DNA oligonucleotide was synthesized either in forward or
reverse complementary direction (for/rev: int 5.2_CCT, int
5.2_CCA, int 5.2_TCA, int 5.2_TCG, int 5.2_AAA, int
5.2_Rep or int 5.13_CCT, respectively). A total of
5 pmol of each forward and reverse oligonucleotide was
50-labeled with [g-32P]-ATP (5000 ci/mmol, Hartmann
Analytic), puriﬁed as mentioned earlier and hybridized
with 1.5-fold molar excess of the respective cold comple-
mentary strand by heating at 95C for 5min and slowly
cooling down to room temperature in hybridization buffer
(10mM Tris–HCl, pH 8, 1mM EDTA, pH 8, 100mM
NaCl). For interference tests, 500 nM refolded Cascade
and 500 nM crRNA (crRNA 5.2 or 5.13) were incubated
in interference buffer 1 (100mM HEPES/KOH, pH 7.0,
100mM NaCl, 10mM ß-Me, 20 ng yeast total RNA) at
70C for 20min to allow loading of crRNA into Cascade
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and then the reaction started by adding 2 nM of 50-labeled
hybridized dsDNA and interference buffer 2 (5mM
MgCl2, 5mM MnCl2, 2mM ATP) at 70
C for 10min.
The reaction was stopped via EtOH precipitation and
loaded on 20% denaturing TBE-polyacrylamide gels or
on 10% sequencing gels (Model S2 sequencing gel electro-
phoresis apparatus, Life Technologies) alongside the low
molecular weight marker or (10–100 nt) or seven speciﬁc
labeled fragments (8–66 nt).
RESULTS
RNA-Seq analyses reveal the processing pattern of
T. tenax crRNAs
One requirement for CRISPR immunity is the processing
of crRNA precursors to yield mature crRNAs. To obtain
a comprehensive view of the processing pattern of
crRNAs in T. tenax, total small RNA was isolated and
sequenced via Illumina HiSeq2000 RNA-Seq method-
ology. T4 PNK treatment of T. tenax small RNAs was
required to facilitate adaptor ligation during RNA-Seq
library construction, which conﬁrms the presence of
50-OH termini (45). Previously, seven CRISPR loci with
a total of 142 spacer sequences were identiﬁed, and
crRNA transcripts were veriﬁed for ﬁve clusters
(TTX_1, 4, 5–7) via northern blot detection, whereas
two clusters (TTX_2–3) showed no distinct processing
pattern (41). In total, 13 357 720 individual sequence
reads were mapped to the T. tenax reference genome
(FN869859). Constitutive crRNA production and a
gradual decline of mature crRNAs from the leader
proximal to the leader distant region within each active
cluster were identiﬁed (Figure 1). The read coverage indi-
cates the relative abundance and the processed termini of
crRNAs from the different CRISPR arrays. Individual
crRNAs for the ﬁrst spacers were represented by up to
1 334 585 reads (spacer 1.1, 10% of total reads), which
demonstrates a massive accumulation of crRNAs in vivo.
All identiﬁed crRNAs contained a clearly deﬁned 50-ter-
minal 8 nt tag (TTX_1: 50-UUUGAAGG-30 or TTX_4–7:
50-AUUGAAAG-30). The 30-termini are gradually
shortened and mostly contain a minimal 2-nt tag
(50-GA-30). Additionally, two spacers (spacer 4.34 and
spacer 5.32) that were not listed in the CRISPR
database could be identiﬁed, increasing the total number
of 144 spacers in T. tenax. In contrast, the CRISPR loci
(TTX_2–3) were inactive and showed no mature crRNAs
with deﬁned termini.
Cas30 and Cas300 are an integral part of the type I-A
Cascade complex
Typical for archaeal subtype I-A CRISPR systems is the
organization of Cascade genes in an operon structure and
their transcription as a polycistronic unit, which includes
individual genes for the helicase (Cas30) and nuclease
(Cas300) domains of Cas3 (41). This organization suggests
a different complex formation than Cascade:Cas3
complexes of the bacterial subtype I-E, in which Cas3 is
recruited to an assembled Cascade bound to target DNA.
To substantiate the protein–protein interactions of the
Cascade complex in vivo, we performed pull-down assays
of T. tenax cell extracts with the C-terminal His-tagged
Csa5 as bait protein (Supplementary Figure S1A). The
interacting proteins were subjected to an in solution
trypsin digest followed by mass spectrometry analyses. In
these experiments, we could identify Cas7, Cas5a, Cas30,
Cas300 and Cas8a2 as interaction partners of Csa5, all six
proteins whose genes are organized in an operon
(Supplementary Table SII). This suggests an alternative
mechanism of Cascade formation, in which the two Cas3
domains are not recruited but are an integral part of the
Cascade complex in advance of the immune response.
Noteworthy, none of the two copies of Cas6 in the
genome of T. tenax were found in the data. Additionally,
we could also detect a second Cas7 homolog (TTX_0235,
40% similarity), produced from a distant cas gene cluster
without an encoded csa5 gene, as a potential interaction
partner of Csa5.
The in vitro assembled Cascade efﬁciently binds a
synthetic mature crRNA
To obtain mature crRNAs with an 8 nt tag (50-AUUGAA
AG-30) and a 50-hydroxyl-terminus, we designed a
ribozyme maturation strategy that overcomes the need
for recombinant Cas6 to be available. A DNA construct
was designed that contained a minimal cis-acting hammer-
head ribozyme fused to the sequence of a mature crRNA
under the control of a T7 RNA polymerase promoter
(Supplementary Figure S2A). The synthetic crRNA was
obtained by in vitro transcription and self-cleavage of the
RNA transcript at 60C. This methodology was tested for
two different crRNA constructs [crRNA 5.2 (50 nt) and
5.13 (54 nt)], resulting in a cleavage efﬁciency of 60%
(Supplementary Figure S2B) (54,55). These synthetic
mature crRNAs were tested for their capability in
complex binding to establish a fully in vitro assembly
strategy of functional Cascade modules. In this procedure,
the co-refolding of the insoluble subunits Cas5a, Cas30,
Cas300 and Cas8a2, in combination with the puriﬁed
proteins Csa5 and Cas7, yielded soluble Cascade
(Supplementary Figure S1A–C). First attempts showed
an increased refolding efﬁciency in the combination of
all six Cascade subunits (41). Therefore, we investigated
the co-refolding of all possible 63 compositions of Cascade
subunits to scan for a minimal stable core of Cas proteins.
Surprisingly, only the co-refolding of all six proteins
resulted in high amounts of soluble protein recovery of
50%, whereas in contrast all other 62 combinations
resulted in negligible amounts (up to 10%) of soluble
protein (Supplementary Figure S3). An up-scaled
protocol for the assembly of the six-protein Cascade
revealed soluble proteins with concentrations of up to
4mg/ml. The assembled Cascade was then incubated for
30min at 65C to remove impurities or misfolded
heat-instable subunits before size-exclusion chromatog-
raphy for screening of Cascade complex formation. The
analysis of the elution proﬁle (12–17ml elution volume)
showed that all six co-refolded proteins eluted in one
fraction, followed by smaller sub-complexes and
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monomeric protein subunits (Figure 2A and
Supplementary Figure S4). The functionality of Cascade
was ﬁrst assayed by analysis of binding to the synthetic
crRNA. The assembled complex was incubated with
crRNA, applied to size-exclusion chromatography and
identical fractions were checked for protein and RNA
content. The ﬁrst fractions of the Cascade proﬁle
co-eluted with the added crRNA. Visible on the
denaturing gel are bands at the expected size of 50 nt
(Figure 2A, crRNA). Two controls showed that the
assembled Cascade was not cross-contaminated with
small RNA from the E. coli expression host (Figure 2A,
RNA) and unbound crRNA was not eluting in the re-
spective fractions (Figure 2A, Cascade). Thus, mature
crRNAs are supporting the Cascade formation, and the
established ribozyme methodology can be used to prepare
synthetic crRNA molecules to be loaded onto Cascade.
In type I-E systems, the subunit Cas7 constitutes the
helical backbone of Cascade that is formed on binding
of the crRNA (31). To verify the RNA-binding activity
of Cas7 in I-A systems, we analyzed T. tenax Cas7 in more
detail. The puriﬁcation strategy for untagged soluble Cas7
resulted in multimeric proteins that eluted at the void
volume from the used gel ﬁltration column indicating
protein complex sizes >600 kDa (Supplementary
Figure S5A). The treatment of Cas7 with DNase I,
RNase A or benzonase identiﬁed a cross-contamination
of Cas7 with E. coli RNAs (<500 nt), which suggests
that Cas7 multimerization is obtained by RNA binding
independent of its sequence (Supplementary Figure S5B).
Transmission electron microscopy (TEM) of this sample
revealed long helical ﬁlaments of up to 50-nm length,
similar to previously reported structural studies of S.
solfataricus (43). Additionally, we could also observe the
occurrence of interlaced ﬁlaments of two Cas7 helices
illustrating the potential for complete coverage of RNA
molecules with Cas7 subunits (Supplementary Figure S6).
To prevent polymeric Cas7 artifacts, an alternative
puriﬁcation strategy of a Cas7-SUMO fusion protein was
established that resulted in monomeric and RNA-free Cas7
(Supplementary Figure S5A and C). This protein prepar-
ation was subsequently used for the in vitro assembly of
Cascade (Figure 2A). A comparison of the crRNA
binding behavior in EMSAs showed the recurrence of
high-shifting multimeric Cas7 structures for the sole Cas7
protein (Figure 2B) and lower shifts and an increased
afﬁnity toward crRNA for Cas7 in a Cascade assembly.
The addition of total yeast RNA or unlabeled crRNA
resulted in similar Cas7 band shifts and underlines an
unspeciﬁc afﬁnity toward RNA for the individual Cas7
subunit (Supplementary Figure S7). In contrast, speciﬁc
binding of Cascade to the synthetic crRNA 5.13 was seen
in EMSAs, with protein concentrations ranging from
0.125–2 mM (Figure 2C). A second synthetic crRNA
(crRNA 5.2) is bound by Cascade with a similar afﬁnity
(Supplementary Figure S8).
Figure 1. Processing of crRNAs in T. tenax. The abundance of crRNAs was veriﬁed by mapping the Illumina HiSeq2000 sequencing reads to the
T. tenax Kra1 reference genome. Sequence coverage (reads) for the seven T. tenax CRISPR clusters (crRNAs are indicated by numbers on the x-axis)
is visualized. The processing sites could be identiﬁed within the repeat elements, generating crRNAs with a 50-terminal 8-nt tag [50-(A/U)UUGAA(A/
G)G-30, underlined] and variable trimming of the 30-ends with most of the crRNAs terminating with a 1–2-nt tag (50-G/GA-30). The trimming sites
for each CRISPR locus are indicated by triangles.
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The exonucleolytically ssDNA cleavage activity of Cas300
is inhibited by the addition of crRNAs
Previous analysis of the nuclease domain of a Cas3
enzyme indicated endo- and exonucleolytic ssDNA
cleavage and revealed an HD motif within its active site,
which is involved in the coordination of transition metal
ions (38). Therefore, nuclease assays with a 93 nt linear
ssDNA substrate were performed to biochemically char-
acterize the T. tenax Cas300 subunit within a coordinated
Cascade structure. Nuclease assays with an assembled
Cascade lacking crRNA showed increasing cleavage
activity at Cascade concentrations of 0.05–0.5mM. At
the highest Cascade concentration, up to 75% ssDNA
was degraded during 10 min incubation at 70C. A time
course cleavage assay with 0.1 mM Cascade demonstrated
degradation of the substrate within 10min (Figure 3A).
The cleavage reaction showed a strict dependence on
divalent metal ions, as increased cleavage of Cascade
was only observed in the presence of Mn2+ ions,
followed by Mg2+ ions, while Ca2+ ions inhibited the
reaction. The highest cleavage rate was observed with
the combination of Mg2+ and Mn2+ ions
(Supplementary Figure S9). Next, we tested the inﬂuence
of crRNA addition on the unspeciﬁc ssDNA nuclease
activity. The used crRNA (crRNA 5.2) and the ssDNA
fragment (int 5.2_CCT for) are not complementary to
each other to prevent the formation of non-cleavable
RNA:DNA hybrids. Cascade was ﬁrst loaded with
crRNA, followed by the addition of the ssDNA substrate
to the reaction to mimic the in vivo situation of Cascade
assembly. The comparison of Cascade ssDNA cleavage
rate at 0.1mM without crRNA and with 0.5mM crRNA
for the identical time points showed an inhibition of the
nuclease activity (Figure 3A). The strongest inhibitory
effect could be observed at 0.05mM added crRNA after
10 min incubation, which resulted in an over twofold
decrease in activity (65% versus 28.5% remaining
ssDNA). The lowered cleavage rate can also be seen for
higher concentrations of crRNA (0.5 mM: 55%, 2.5 mM:
45% uncleaved substrate), but is less signiﬁcant, presum-
ably due to hybrid formation of excess crRNAs
(Figure 3B). To verify that Cas300 is the sole ssDNA
nuclease domain within the archaeal Cascade, we
aligned the T. tenax Cas300 with the previously
characterized Methanocaldococcus jannaschii Cas300
(MJ0384) sequence and introduced mutations of three of
the four highly conserved residues of the HD domain
motif (H19A, H55A and D56A) that are expected to in-
activate exonuclease cleavage (37). The produced Cas300
mutants were isolated and puriﬁed according to the
wild-type Cas300 puriﬁcation protocol and assembled
within Cascade via the co-refolding procedure
(Supplementary Figure S10). Each Cas300 mutant showed
a deﬁciency in ssDNA nuclease activity, most dramatically
observed for D56A (12% cleaved ssDNA), followed by
H19A (18% cleaved substrate) (Figure 3C).
Cascade-mediated interference is dependent on crRNA and
the protospacer DNA
Next, the assembled I-A Cascade was tested for cleavage
of dsDNA in dependence of the spacer encoded crRNA to
show in vitro type I-A Cascade-mediated interference.
First, short dsDNA fragments were designed that mimic
viral protospacer DNA. The spacer sequence 5.2 (40 bp)
was ﬂanked by random sequences on both sides
(25 bp each). Directly upstream of the spacer the PAM
sequence CCT was integrated. The PAM sequence CCN
was identiﬁed in S. solfataricus on the basis of viral
Figure 2. Cascade assembly and RNA binding. (A) The Cascade subunits (Csa5, Cas7, Cas5a, Cas30, Cas30 0 and Cas8a2) were assembled via a co-
refolding procedure of insoluble recombinant proteins, incubated with synthetic crRNA 5.2 (crRNA) or no RNA (RNA), and protein interaction
was veriﬁed via size-exclusion chromatography. In all, 15% SDS–PAGE of individual fractions (fractions 10–18) shows distinct protein bands of
assembled Cas protein subunits. The Cascade-containing fractions were additionally analyzed for bound RNA content by 10% Urea-PAGE. A
protein-free sample served as a running control (Cascade). (B) A comparison of the EMSAs for crRNA binding by the individual Cas7 subunit
(lanes 1–7: 0, 0.2, 0.5, 1, 2, 4, 5mM) or Cas7 assembled into Cascade (lanes 8–10: 0.5, 2, 5 mM) on 1% agarose gels demonstrates the formation of
high shifts for Cas7 alone and lower, more diffuse shifts for Cascade. (C) EMSAs veriﬁed the binding of the 50-[g-32P]-ATP labeled crRNA 5.13 by
Cascade (with Cas7 puriﬁed via a SUMO-fused construct) in increasing concentrations (lanes 1–6: 0, 0.125, 0.25, 0.5, 1, 2 mM) and in the presence of
yeast RNA via 6% native PAGE.
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BLAST hits of spacer targets (10). The non-target
(int 5.2_CCT for, crRNA non-complementarity) or the
target DNA strand (int 5.2_CCT rev, crRNA complemen-
tarity) was 50-labeled and hybridized with 1.5-fold excess
of the complementary cold strand to obtain two labeled
dsDNA fragments. The synthetic mature crRNA con-
struct 5.2 was supplied by hammerhead self-cleavage and
ﬁrst loaded into Cascade before the addition of the
dsDNA substrates, the metal ions Mg2+ and Mn2+, as
well as ATP. The separation of cleavage products via
20% denaturing-PAGE identiﬁed a Cascade-dependent
degradation pattern of the dsDNA substrates with differ-
ences in fragment length for the non-target and target
strand (Figure 4A). As a control, the Cas300 nuclease
mutant D56A was assembled into Cascade, which
showed no cleavage activity of the protospacer DNA.
Cascade loaded with a synthetic crRNA 5.13 that is not
complementary to the DNA target showed also no
dsDNA cleavage activity demonstrating crRNA-
mediated target guidance. In return, the reaction was per-
formed using the spacer sequence 5.13 with identical
ﬂanks in the dsDNA substrate as used before
(Figure 4B). Accordingly, only the matching crRNA
5.13 was capable to guide the Cascade-mediated
cleavage of the dsDNA substrate, whereas neither the
incorporated crRNA 5.2 nor the Cascade mutant Cas300
D56A showed nuclease activity. The cleavage pattern of
the non-target and target strand was similar for dsDNA
5.13 in comparison with dsDNA 5.2. Therefore, the
cleavage products of the interference reaction with the
labeled non-target and target strand of each dsDNA
substrate 5.2 or 5.13 were separated on 10% sequencing
gels to specify the fragment lengths (Supplementary
Figure S11). Each reaction was loaded next to a marker
with ssDNA fragments of 10–100 nt length and a mixture
of seven ssDNA fragments of 8–66 nt length to pinpoint
the dominant cleavage products. Cleavage sites were
observed in the middle of the non-target strand within
the protospacer (at position 43–47 nt), and smaller 50-
terminal fragments were generated with a minimal
length of 10 nt (Figure 4C). The target strand is cleaved
over its entire length, with smallest fragments of 9 nt. The
comparison of both DNA substrates showed no signiﬁ-
cant differences in the fragmentation pattern, indicating
a sequence unspeciﬁc cleavage of Cascade in dependence
of the position within the R-loop structure (Figure 4D).
The Cascade reconstitution platform allows the
identiﬁcation of PAM-dependent target DNA cleavage
The co-refolded Cascade in combination with in vitro
processed crRNA provides an active interference
complex cleaving dsDNA in a RNA sequence-dependent
manner. This set up allows the modulation of individual
components and to test their inﬂuence on Cascade-
mediated interference. First, the Cas300 mutants H19A,
Figure 3. Type I-A Cascade cleaves ssDNA unspeciﬁcally and is inhibited by crRNA. (A) Cascade (0, 0.05, 0.125, 0.25, 0.5 mM) was incubated with
a 50-[g-32P]-ATP labeled ssDNA fragment (int_5.2 CCT for) in the presence of Mg2+ and Mn2+ ions and the nucleolytic cleavage reaction was
resolved on 15% denaturing gels. After 1–10-min incubation at a ﬁxed Cascade concentration of 0.1 mM, >70% of the substrate is cleaved. In the
presence of 0.5 mM unlabeled crRNA, the reaction is inhibited. (B) This observation was tested in the presence of 0, 0.05, 0.5 and 2.5 mM crRNA, and
the amount of remaining substrate estimated via line proﬁle plots (Image J) was plotted for three different reaction times (1, 2, 10min) and reactions
performed in triplicate. (C) Cas30 0 subunit with HD domain mutations (H19A, H55A, D56A) was assembled into Cascade and then tested in ssDNA
cleavage assays.
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H55A and D56A were assembled into Cascade and tested
for their ability to cleave dsDNA substrates (Figure 5A).
All three mutants were impaired in dsDNA cleavage. The
H19A and D56A mutants showed no activity for the non-
target or target strand, while H55A is strongly reduced in
dsDNA cleavage. Next, the effect of different PAM se-
quences on the in vitro interference reaction was assayed.
It should be noted that Cascade recognizes PAM se-
quences as so-called target interference motifs that might
slightly differ from the PAM sequence recognized during
adaptation (56). Owing to missing viral targets of T. tenax
spacers, the exact PAMs are not known. Detailed analysis
of S. solfataricus CRISPR systems revealed CCN
sequences located 50 to the DNA strand corresponding
to the crRNA (non-target strand) as functional PAMs
(10,57), and computational studies identiﬁed the TCN
motif as a potential PAM (56,58). Therefore, the
designed dsDNA protospacer substrate 5.2 was modiﬁed
upstream in the spacer-adjacent three base pair motif,
while the spacer and the ﬂanking sequences remained
identical. The tested dsDNA substrates contained the
PAM sequences CCT, CCA, TCA, TCG, AAA and a
motif identical to the 50-tag of the crRNA (mimicking
self-targeting at the CRISPR locus) (Figure 5B). The
interference reaction showed similar Cascade cleavage
patterns of dsDNA for the PAM CCT and CCA,
Figure 4. Interference activity of in vitro assembled type I-A Cascade. (A) The assembled Cascade complex is loaded with crRNA 5.2 for 20min at
70C, and the interference reaction is started with the addition of ATP, Mg2+, Mn2+ and the dsDNA substrate (in_5.2 CCT), which is either
50-[g-32P]-ATP labeled on the non-target (forward) or the crRNA target strand (reverse). Cleavage reactions were stopped at three different time
points (1, 5, 10min at 70C). The reaction products of the cleaved dsDNA were separated on 20% denaturing gels. The non-matching crRNA 5.13
and the Cas30 0 D56A mutant are used as controls. (B) In parallel, the crRNA 5.13 is loaded into Cascade, and cleavage of the matching dsDNA
substrate (in_5.13 CCT) is visualized. (C and D) The cleavage products are analyzed on 10% Urea-PAGE for each strand (in_5.2 CCT for/rev and
in_5.13 CCT for/rev) with two different markers (Supplementary Figure S9). The cleavage sites are marked within the proposed R-loop structure that
is formed during the interference reaction [(C) dsDNA 5.2, (D) dsDNA 5.13].
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conﬁrming that CCN motif is a PAM that allows DNA
target cleavage. A reduced activity was observed for the
TCA PAM, while substrates with the TCG, AAA or the
50-tag motif were not cleaved by Cascade.
DISCUSSION
Type I CRISPR-encoded interference is mediated by a
crRNA-guided Cascade complexed with Cas3 to degrade
the foreign target DNA. Here, we described the produc-
tion and assembly of an archaeal type I-A Cascade with
co-refolded recombinant Cas proteins and synthetic
crRNA transcripts, which resulted in an active complex
capable of crRNA-guided degradation of dsDNA in
dependence of PAM sequences.
The analysis of T. tenax RNA-Seq read mapping
revealed the mature crRNA termini and conﬁrmed
previous northern blot analyses, which indicated that
T. tenax harbors ﬁve highly active CRISPR loci and two
inactive CRISPR loci (41). These inactive and active
clusters contain conserved motifs for transcription initi-
ation and differ mainly in their respective repeat sequences
(seven base exchanges and one base length difference).
Therefore, it is plausible that this repeat is not processed
by the two encoded Cas6 proteins. Accordingly, in type
III-A systems, crRNAs or their precursors cannot be
detected in Cas6 deletion mutants suggesting degradation
of the primary transcript (59). Alternatively, the
transcription of the two inactive loci could be regulated
by an unknown mechanism. To engineer functional syn-
thetic crRNAs, the in vivo processing of mature crRNAs
by Cas6 had to be mimicked, as soluble recombinant Cas6
was not available. The technique of fusing a cis-acting
hammerhead ribozymes to RNA transcripts to obtain
deﬁned termini (54,55) was adapted for the production
of crRNAs, which resulted in 8 nt tags with 50-hydroxyl
ends (Supplementary Figure S2A and B). This method-
ology allows the in vitro production of crRNAs that
start without the guanosine base that is required for
proper T7 RNA polymerase transcription initiation. The
RNA-Seq data additionally revealed gradually degraded
30-termini for all crRNAs. The used synthetic crRNAs
contained a 2 nt tag (50-GA-30), which was observed for
the majority of crRNA reads. The trimming of the
crRNAs’ 30-end is typically observed in many different
bacteria and archaea, but the exact mechanism is not
known (60,61). It is likely that Cas6-processed crRNAs
are protected by Cascade proteins binding to the
conserved 50-end, whereas the free 30-ends are
unspeciﬁcally trimmed by cellular RNases due to a
missing secondary structure or that crRNAs are unstable
at elevated temperatures (62,63). For organisms with
multiple encoded CRISPR-Cas effector complexes,
distinct crRNA species with varying 30-ends might be
sorted between complexes in dependence of their length
(64). These potential parameters for crRNA loading into
Figure 5. Analysis of Cas30 0 mutants and PAM recognition for in vitro assembled type I-A Cascade. (A) The Cas30 0-constructed mutants
(H19A, H55A, D56A) were assembled into Cascade and tested for dsDNA cleavage. (B) The dsDNA substrate 5.2 was mutated to include the
indicated 3-bp long PAM sequences (CCT to CCA, TCA, TCG, AAA or a PAM identical to the crRNA 8-nt tag). Cascade-mediated interference
reactions were performed with either 50-[g-32P]-ATP labeled non-target (forward) or the crRNA target strand (reverse) as a substrate, while Cascade
was loaded with the spacer matching crRNA 5.2. The loaded non-matching crRNA 5.13 served as a negative control.
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recombinant Cascade could be tested by engineering
multiple modiﬁed synthetic RNAs. Other possible appli-
cations for the use of synthetic crRNA transcripts are dye-
labeled RNA constructs for smFRET measurements or
crRNA-Cascade cross-linking with photoreactive nucleo-
tide analogs that facilitates detailed information about the
RNA structure and motion during complex formation and
a precise mapping of the cross-link between crRNA and
Cas protein subunit (65–67).
Previous research focused on the detailed analysis of the
E. coli type I-E Cascade function and structure (19,31).
One main feature of the type I-E interference mechanism
is a separation into the Cascade module that is binding
the crRNAs recognizing the matching DNA target and the
Cas3 protein, which is recruited by Cascade to the
crRNA:dsDNA R-loop structure. The E. coli Cascade is
built up by the subtype speciﬁc subunits Cse1 and Cse2
that are proposed to interact with the DNA target, the
conserved crRNA binding subunits Cas7 and Cas5e and
the pre-crRNA cleaving endoribonuclease Cas6e
(18,29,30). From a mechanistic point of view, this arrange-
ment guarantees a streamlined processing of the pre-
crRNA transcripts, immediate crRNA protection and
the scanning for the complementary DNA target,
localized within one protein complex. Additionally, the
transcription of pre-crRNAs and cascade genes are
strictly repressed by the global regulator H-NS and
activated with the help of the transcription factor LeuO,
ensuring a fast response to a viral attack (68–70).
In this study, we analyzed an archaeal type I-A CRISPR-
Cas system, which showed remarkable differences in the
assembly of Cascade and the crRNA production. A
typical feature found in archaeal genomes is the splitting
of the two Cas3 domains into separate genes (Cas30:
helicase domain, Cas300: nuclease domain) and a gene organ-
ization into one cascade genes operon that can be regulated
by changes of the environmental parameters (41). Similar to
type I-E Cascade, the crRNA binding subunits cas7 and
cas5a and two subtype-speciﬁc subunits csa5 and cas8a2
are encoded within the operon. However, two cas6 genes
are encoded separately at distant locations in the genome.
Pull-down assays supported that the genomic cas gene or-
ganization mirrors the Cas protein assembly, as both Cas3
subunits, Cas7, Cas5a and Cas8a2 were interacting with
Csa5. The Cas6 protein could not be identiﬁed
(Supplementary Table SII). In agreement, the co-refolding
of all possible protein combinations showed the necessity of
Cas3 for the formation of a stable Cascade complex,
indicating that the two Cas3 subunits are not recruited but
are rather an integral part of the Cascade I-A complex. In
contrast to type I-E systems, pre-crRNA transcription and
crRNA production appears to be constitutive, as evidenced
by the high abundance of crRNAs detectable in RNA-Seq
data. Therefore, regulation of Cascade immunity appears to
rely on the activation of Cas protein production. The tran-
scription of the Cascade genes might be activated by the
encoded regulator protein Csx1 (Csa3), which is followed
by assembly of Cascade:Cas3 and immediately loaded with
crRNA to cleave the protospacer DNA target (71). A
possible reason for the differences in Cascade assembly
might be the thermophilic lifestyle of T. tenax, which
would make a later recruitment of Cas3 to Cascade
assembled in an R-loop structure under elevated tempera-
tures challenging. Interestingly, type I-A systems are exclu-
sively found in thermophilic organisms, supporting the
evolutionary conservation of this alternative Cascade for-
mation strategy (6).
The established assembly of the T. tenax Cascade
allowed us to investigate the type I-A interference
reaction and the role of individual subunits in more
detail. In Cascade nuclease assays, Cas300 was identiﬁed
as the primary deoxyribonuclease subunit, cleaving linear
ssDNA substrates exonucleolytically in the dependence of
the divalent Mg2+ and Mn2+metal ions. Mutations in the
conserved HD domain motif (H19A, H55A and D56A)
inhibited the cleavage activity. The large group of HD
domain proteins comprises enzymes that are primarily
involved in nucleic acid metabolism and signal transduc-
tion and react on a broad range of substrates, including
ssDNA, RNA and R-loop structures (37,72). The degrad-
ation of ssDNA substrates by the Cas300 subunit was pre-
viously characterized for different Cascade subtypes from
M. jannaschii, S. thermophilus or Thermus thermophilus,
and a crystal structure revealed the active site with two
bound metal cations (37–39). The observed unspeciﬁc
cleavage of ssDNA by Cas300 in vitro would pose a
problem within the cell. The addition of non-matching syn-
thetic crRNA to the nuclease assays indicated an inhibition
of this background cleavage activity. This suggests that
Cascade might ﬁrst bind crRNA, which inhibits the unspe-
ciﬁc ssDNA cleavage until the correct dsDNA target is spe-
ciﬁcally located. Another example for the interplay
between Cascade subunits was observed for the binding
of crRNAs. The puriﬁcation procedure, EMSA assays
and TEM imaging conﬁrmed that T. tenax Cas7 binds
unspeciﬁcally to both crRNAs and other small RNA con-
taminants. This interaction resulted in the formation of
long helical Cas7 multimer structures. The observation of
helical Cas7 ﬁlaments was also made for a Cascade
sub-complex of the subunits Cas7 and Cas5a of S.
solfataricus (43). The cryo-electron microscopy structure
of the I-E Cascade revealed a seahorse-like shape, in
which six copies of the Cas7 subunit are forming the
backbone, combined to a Cascade stoichiometry of 1
Cse1, Cas5e, Cas6e, 2 Cse2 and 6 Cas7 (18,31). The
binding behavior of T. tenax Cas7 embedded in I-A
Cascade changed signiﬁcantly. The shifting of crRNA
appeared lower during EMSA assays, the gel ﬁltration
showed no formation of extended Cas7 multimers and no
helical structures were observed in TEM pictures. These
observations indicate a coordinated assembly of I-A
Cascade and a capping mechanism by other Cascade
subunits that block Cas7 from forming extended
multimeric ﬁlaments. The exact stoichiometry for I-A
Cascade could not be determined as the amount of
functional refolding is not known. Future work on the
Cascade structure via TEM, crystallization or native mass
spectrometry is required to address these questions.
In interference assays the assembled I-A Cascade
exhibited crRNA-mediated cleavage of dsDNA molecules.
In the targeting event, Cascade facilitates base pairing of
the crRNA with the complementary target strand and
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additional displacement of the non-target strand to
produce the R-loop structure (33,35). An open question
is the nature of the crRNA seed sequence speciﬁcally for
the type I-A CRISPR-Cas system, deﬁned as the minimal
sequence complementarity of crRNA and target DNA for
binding (32,73). The existence of an adjacent PAM was
shown to be essential for directing DNA cleavage (57).
Functional PAM sequences for the T. tenax I-A Cascade
were CCA or CCT, whereas other ﬂanking sequences
yielded a reduced (TCA) or impaired activity (TCG).
The origin of the T. tenax spacers is not known.
Therefore, the established interference assay allowed us
to identify this basic requirement for Cascade-mediated
cleavage and can be used to complement plasmid-based
in vivo assays that determined the PAM sequences in vivo
for I-A and I-B systems (11,56,74,75). The main function
of the PAM is the discrimination between host CRISPR
loci DNA and protospacer/target sequences. Cascade ﬁrst
screens for the speciﬁc PAM followed by a helical desta-
bilization and strand invasion of the crRNA, which leads
to the R-loop formation (61,76). An outstanding question
is the mechanism for the identiﬁcation of the correct
PAM, which triggers the crRNA-loaded Cascade for tar-
geting. Two candidates Csa5 and Cas8a2 that are
described as the small and large subunit in Cascade
might interact with the DNA target and/or recognize the
PAM (5,77). The Cascade-mediated interference assays
reﬂect the stepwise degradation of the dsDNA, as Cas300
ﬁrst cleaves in the middle of the looped out non-target
strand (at position 43–47 nt) followed by a gradual
cleavage in 30–50 direction. In a second step, the target
strand is then cleaved over the entire length also in 30–50
direction, which was reported previously for other
members of the Cas3 family (37–39). The identiﬁed
minimal cleavage products are similar to ones found in
the type I-E system with 8–10-nt fragment length, which
suggests a conserved cleavage mechanism (35).
In conclusion, the established in vitro assembly and
interference activity protocols of a type I-A Cascade with
synthetic crRNA molecules highlight similarities and dif-
ferences between this archaeal interference complex and
the type I-E Cascade. These studies are expected to aid in
the assembly of other Cascade complexes to help us to
understand commonalties and differences in the evolution
of the diverse type I Cascade machineries.
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